• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等
评价技术与方法

超声心动图参数、血清Adropin水平与扩张型心肌病患者治疗效果的相关性分析

展开
  • 1.信阳市人民医院超声诊断科, 河南 信阳 464000;
    2.郑州市第七人民医院超声诊断科, 河南 郑州 450000
金凤阳,女,主治医师,研究方向:超声诊断

收稿日期: 2025-03-20

  修回日期: 2025-03-27

  录用日期: 2026-01-07

  网络出版日期: 2026-01-07

Correlation Analysis of Echocardiographic Parameters, Serum Adropin Levels,and Treatment Outcomes in Patients with Dilated Cardiomyopathy

Expand
  • 1.Department of Ultrasound Diagnosis, Xinyang People′s Hospital, Henan Xinyang 464000, China;
    2.Department of Ultrasound Diagnosis, the Seventh People′s Hospital of Zhengzhou City, Henan Zhengzhou 450000, China

Received date: 2025-03-20

  Revised date: 2025-03-27

  Accepted date: 2026-01-07

  Online published: 2026-01-07

摘要

目的:探讨扩张型心肌病(DCM)患者治疗前后超声心动图参数、血清能量平衡相关蛋白(Adropin)水平变化,并分析其与治疗效果相关性及其评估价值。方法:回顾性选取2022年5月~2024年5月本院96例DCM患者为研究对象,均予以常规治疗,依据治疗3个月后治疗效果将其分为有效组70例、无效组26例,比较两组临床资料及超声心动图参数[左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)、左心房内径(LAD)]、血清Adropin水平。分析超声心动图参数、血清Adropin水平对治疗效果的影响,并分析其与治疗效果的相关性。分析超声心动图参数、血清Adropin对治疗效果的评估价值。结果:有效组治疗后LVESV、LVEDV、LAD、血清Adropin水平低于治疗前,且低于无效组(P<0.05);多因素Logistic回归分析显示,在校正了年龄、病程、NYHA心功能分级后,LVESV、LVEDV、LAD、Adropin仍是治疗效果的相关影响因素(P<0.05);偏相关性分析显示,LVESV、LVEDV、LAD、Adropin与治疗效果呈负相关(P<0.05);治疗1个月后LVESV、LVEDV、LAD、血清Adropin单项及联合评估治疗效果的AUC值分别为0.769、0.757、0.790、0.754、0.916,且联合评估的AUC值大于各指标单独评估(P<0.05)。结论:LVESV、LVEDV、LAD、血清Adropin水平为DCM患者治疗效果的相关影响因素,且与治疗效果呈负相关,联合检测其水平对治疗效果具有一定评估价值。

本文引用格式

金凤阳, 杨帆, 刘元君, 翟婷婷 . 超声心动图参数、血清Adropin水平与扩张型心肌病患者治疗效果的相关性分析[J]. 中国药物评价, 2025 , 42(6) : 441 -441-446 . DOI: 10.2095-3593.2026.010002

Abstract

Objective: To investigate the changes in echocardiographic parameters and serum Adropin levels in patients with dilated cardiomyopathy (DCM) before and after treatment, and analyze their correlation with treatment efficacy and their evaluation value. Methods: A total of 96 patients with DCM who were treated in our hospital from May 2022 to May 2024 were selected retrospectively. All patients were given conventional treatment, and they were divided into an effective group of 70 patients and an ineffective group of 26 patients based on the therapeutic effect after 3 months of treatment. The clinical data and echocardiographic parameters [left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), left atrial diameter (LAD)], serum Adropin levels were compared between the two groups. The impact of echocardiographic parameters and serum Adropin levels on the therapeutic effect was analyzed, and their correlation with the therapeutic effect was analyzed. The evaluation value of echocardiographic parameters and serum Adropin on the therapeutic effect was analyzed. Results: After treatment, the LVESV, LVEDV, LAD, and serum Adropin levels in the effective group were lower than those before treatment and lower than those in the ineffective group (P<0.05); multivariate Logistic regression analysis showed that after adjusting for age, disease duration, and NYHA functional classification, LVESV, LVEDV, LAD, and Adropin were still associated with treatment efficacy (P<0.05). Partial correlation analysis showed that LVESV, LVEDV, LAD, and Adropin were negatively correlated with treatment efficacy (P<0.05).After one month of treatment, the AUC values for the individual and combined assessment of LVESV, LVEDV, LAD, serum Adropin, and the therapeutic effect were 0.769, 0.757, 0.790, 0.754, and 0.916, respectively. The AUC value for the combined assessment was greater than that for each individual indicator (P<0.05). Conclusion: LVESV, LVEDV, LAD, and serum Adropin levels are factors associated with the therapeutic efficacy in patients with DCM, and are negatively correlated with the therapeutic efficacy. Combined detection of their levels has certain evaluation value for the therapeutic efficacy.

参考文献

  [1] 陆爱民,赵艳,刘宝宝. 血清β2-MG、miR-133a联合检测对扩张型心肌病患者预后的评估价值[J]. 岭南心血管病杂志,2020,26(6):685-688.
     [2] 王岩,陈磊. 扩张型心肌病患者的DC、AC、HRV检测及其与心功能的相关性[J]. 海南医学,2022,33(12):1505-1507.
     [3] 陈火梅,赖玉琼,莫展,等. 超声心动图评估主动脉瓣置换术后病人心功能及中远期预后的临床价值[J]. 中西医结合心脑血管病杂志,2023,21(5):895-899.
     [4] 范彩逢,王振华,张守彦,等. 重症心力衰竭患者血清Adropin和炎性趋化因子水平变化及其与左心室重构和预后的关系[J]. 热带医学杂志,2020,20(4):530-533.
     [5] 中华医学会心血管病学分会,中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志,2018,34(5):421-434.
     [6] 廖玉华. 中国扩张型心肌病诊断和治疗指南:创新与转化[J]. 临床心血管病杂志,2018,34(5):435-436.
     [7] 陈志强,杨关林. 中西医结合内科学[M]. 3版. 北京:中国中医药出版社,2016:133-134.
     [8] 黄磊磊,幸红燕,周果. 扩张型心肌病慢性心力衰竭患者血清POSTN、STAT3水平变化及其临床意义[J]. 山东医药,2023,63(31):28-32.
     [9] 叶丽虹,余小君,吴轲,等. 超声心动图参数联合血清NT-pro BNP、suPAR、PTX-3预测慢性心力衰竭患者预后的临床研究[J]. 现代生物医学进展,2023,23(18):3479-3483.
     [10] 苏洁,王书伟,马维东,等. 超声心动图参数联合血清Adropin、SDC4对急性STEMI患者早期静脉溶栓预后的预测价值[J]. 中国急救复苏与灾害医学杂志,2024,19(8):993-996.
     [11] 徐艳,余敏,王璐璐. 改良早期预警评分联合超声心动图及血清标志物预测老年慢性心力衰竭病人长期预后的临床价值[J]. 中西医结合心脑血管病杂志,2022,20(24):4572-4576.
     [12] 吕佳仁,江惠琼,许德星. 超声心动图参数联合心电图T波振幅评估扩张型心肌病患者左室收缩功能的临床价值[J]. 临床超声医学杂志,2023,25(12):990-995.
     [13] Berezina TA,Berezin OO,Novikov EV,et al. Irisin Predicts Poor Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Low Levels of N-Terminal Pro-B-Type Natriuretic Peptide[J]. Biomolecules,2024,14(12):1615-1625.
     [14] 赵颖超,额尔敦其木格,戴军有,等. 急性心力衰竭患者血清Adropin、sST2、Gal-3水平与预后的关系分析[J]. 现代生物医学进展,2020,20(7):1326-1330.
     [15] 廖贵娟,陶伟. 冠心病合并心力衰竭患者血清Adropin、sST2、BNP水平与预后的关系分析[J]. 标记免疫分析与临床,2020,27(12):2112-2116.
     [16] 梁善福,孙运,张申伟,等. 急性失代偿心力衰竭病人出院时sST2、Adropin、RDW水平与6个月内不良事件发生的关系[J]. 中西医结合心脑血管病杂志,2022,20(22):4181-4184.
     [17] 宋势波,欧阳斯华,李艺玲. 超声心动图联合血清β2-微球蛋白、同型半胱氨酸评估扩张型心肌病患者心力衰竭风险的价值[J]. 临床超声医学杂志,2022,24(6):465-468.
     [18] 周秀,李毓娟,赵小瑞. 冠心病不稳定型心绞痛病人血清ENS、adropin表达及其与预后的关系[J]. 中西医结合心脑血管病杂志,2022,20(10):1823-1826.
文章导航

/